NYSE:NVO
Novo-Nordisk (NVO)
Financials 
Technical Analysis 
Aug 8, 2026, 12:00 amThis summary was created by AI, based on 32 opinions in the last 12 months.
Novo Nordisk (NVO) is facing significant competition in the GLP-1 drug market, primarily from Eli Lilly (LLY), which has emerged as a leader due to its aggressive marketing and advancements in research and development. Many experts suggest that while NVO has a historically strong franchise, particularly with its weight-loss drug, its current stock performance is under pressure and not projected to see substantial earnings growth in the near term. Some analysts consider NVO to be a value trap, pointing to the challenges it faces, including management changes and increasing competition, particularly from generics. Despite this, there are opinions that highlight the long-term potential of NVO, especially with regards to the growing obesity and metabolic health markets. However, short-term caution is advised, and many experts prefer LLY due to its better prospects and market positioning.
Probably one of the world’s largest oil field service companies. Involved in manufacturing of equipment. Big builder of drilling rigs for the drilling companies. Very diversified in a lot of different markets. This is actually a great long-term play on the growth of the energy industry. If you don’t own, wait for a bit of a back off before stepping in.
Lost an Express Scripts (ESRX-Q) contract for its synthetic insulin medicine because of price. Although that is a headwind, it is not material. Has a very broad base of profits and sells its products throughout North America and Europe. Also likes that manufacturing insulin is almost a craft, which means it is much more resistance to generics in the long-term. Not necessarily cheap at about 20X trailing earnings, but it’s a business that has pretty strong visibility into decent high single digit top line growth and much better operating profit growth for the next few years. Have done a great job of returning cash to shareholders through buybacks and dividend increases.
Charles LannonLargest manufacturer of insulin globally and has been taking share from Eli Lilly (LLY-N) for years. Stock sold off because it had problems getting FDA approval for a new type of diabetes drug that has been approved in Europe and Japan.
Charles Lannon
David DriscollDavid DriscollDavid DriscollCharles LannonDavid DriscollDavid DriscollDavid DriscollDavid DriscollDavid DriscollDavid DriscollDavid Driscoll'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Leading insulin maker globally. Diabetes is supposed to grow by 20% over the next 20 years, especially in countries like India and China. This is a big pool for everybody to do well, in spite of competition coming in. Usually every 5 years, this company will have a big run and then start to fall back as their growth rate begins to decline waiting for that time when they can bring new products to market, which will then be the leading edge. In the last year or so, they have been suffering only from the standpoint that one of the HMO providers has decided not to use their insulin drug. Because of this, their earnings growth has declined to roughly the 10% range, but that could be temporary. News on the weekend indicated that their Liraglutide 3 enzyme is the one injection per day that has proven it will help with weight loss for people who are diabetic. Stock is fully valued so wait for an entry point.